The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
about
Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juiceEnterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosisMembrane transporters in drug developmentSummary of information on human CYP enzymes: human P450 metabolism data.Metabolism-based drug interactions involving oral azole antifungals in humans.Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.P-glycoprotein and bioavailability-implication of polymorphism.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme inductionInfluence of ketoconazole on azimilide pharmacokinetics in healthy subjects.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Review article: monitoring of immunomodulators in inflammatory bowel disease.The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?Drug interactions during therapy with three major groups of antimicrobial agents.Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants.Drug interactions in childhood cancer.The drug transporter-metabolism alliance: uncovering and defining the interplay.Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences.Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.Azole interactions with multidrug therapy in pediatric oncology.Loss of orally administered drugs in GI tract.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Update on drug interactions with azole antifungal agents.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes.Inhibitory effect of nitric oxide on the induction of cytochrome P450 3A4 mRNA by 1,25-dihydroxyvitamin D3 in Caco-2 cells.CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.Evaluation of gastrointestinal absorption and metabolism.First-pass effect: significance of the intestine for absorption and metabolism.An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine.Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients.Effect of fluconazole on the pharmacokinetics and pharmacodynamics of oral and rectal bromazepam: an application of electroencephalography as the pharmacodynamic method.Effect of mibefradil on CYP3A4 in vivo.Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin.Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers.Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study.
P2860
Q28204828-210B333B-8882-4BF4-9C57-26D471ACA388Q28367522-1D2D7C49-5709-414C-8A91-44AEDA076F3AQ29616802-3884E552-031D-4348-8F6D-DC235CE92B4BQ32103802-685A28C9-14EB-4123-B674-C75D0431F80BQ33719828-280775A1-B9DF-4BA0-8081-24A15F8DEBFFQ33887999-4661EBF2-EFBE-4503-85E4-1470370732AAQ34093099-43BC4A33-1124-419A-97B4-14EF6E700575Q34430456-C1AA452E-2D2A-4661-943C-76BB5575637DQ34644860-E5A84675-3268-4C3A-A375-7C85C973BF34Q35802166-FA82622B-C0AD-4939-ACA7-D50077A40C27Q35826541-66DBD15B-A375-46CC-9C38-D2DDA0B488E1Q35876954-2DB6890C-AE31-43AA-A2E1-5C4A42ABC3EBQ36041146-3BB83E60-36AE-4498-B5E4-4A2E0F33014DQ36186945-28ABDA2F-9C32-4612-A130-549B0887D604Q36429699-655EA5C0-690F-4A4A-A711-200ECC51C045Q36662912-CE12D680-546C-42BC-87E1-0C5B20AB47E0Q36898141-B4A3928F-0C20-48B1-9C04-39CB8C36DF8FQ37485904-1FA6C2D2-FC7C-4DCB-B2B4-3C304D14FD94Q37650803-90FC554D-F3C9-482D-AF3C-B6B05054FD4BQ37836908-DF4642A7-9250-43B0-83AB-AE226B900B67Q37920916-019FC4B9-FB51-4882-882C-85A9A5E52427Q37924869-E3EE6CD3-4AD5-4DDC-9CEB-EA9723440DE5Q38015710-C510E0E6-36EB-4C0F-9290-98B06F8AF85CQ38130231-B9EBE0FC-50F0-4592-B2D7-8CAF97E9F780Q38183877-3CC04200-04A7-49ED-9CF5-B41D487EF477Q38549824-413E6522-6BDC-434D-B2AC-33A2EFBCCC65Q38748975-1082810A-2549-4EBB-9D82-96AE3D4C8D89Q39652863-43F7343C-5139-4E9E-9768-92213111B1B1Q40854554-F4724E1A-01F9-4BBE-8DE1-BB688AE46863Q41596164-222C98D1-CB1F-48D9-ADD2-853C8D24A52FQ41676780-D77EAA75-8DB9-415E-9A63-637D3D879CFBQ41684485-4304CFEA-19F7-40FC-A198-6AD328B3F07DQ42050629-D008A10A-B0DF-44BB-9994-87C7C6C6A251Q43551282-42D376AC-307E-4477-8B74-52A212A5B21AQ43878866-BADF3819-44B1-4710-97D0-B51BB9DBFE0EQ44601136-2FDB4156-2A33-4723-9B00-AA51A56E3B23Q46378358-416AA1CE-4CBF-4C10-ACC9-7CE4E9564D82Q46391221-319C5C45-D496-48D6-933F-5DD8D604D040Q46607017-3D2DD100-7601-4BBB-B7F0-E60052810F3EQ46952935-97B327C0-74E1-4CBE-A42F-DA915B8B2862
P2860
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
The effects of ketoconazole on ...... oavailability of cyclosporine.
@en
The effects of ketoconazole on ...... oavailability of cyclosporine.
@nl
type
label
The effects of ketoconazole on ...... oavailability of cyclosporine.
@en
The effects of ketoconazole on ...... oavailability of cyclosporine.
@nl
prefLabel
The effects of ketoconazole on ...... oavailability of cyclosporine.
@en
The effects of ketoconazole on ...... oavailability of cyclosporine.
@nl
P2093
P1476
The effects of ketoconazole on ...... oavailability of cyclosporine.
@en
P2093
P2860
P356
10.1016/0009-9236(95)90067-5
P407
P577
1995-07-01T00:00:00Z